| DCAP008 |
QS-21
Featured
|
QS-21, an immunostimulatory saponin, could be used as a potent vaccine adjuvant. QS-21 stimulates Th2 humoral and Th1 cell-mediated immune responses through action on antigen presenting cells (APCs) and T cells. QS-21 can activate the NLRP3 inflammasome with subsequent release of caspase-1 dependent cytokines, IL-1β and IL-18[1][2][3]. |
|
| DC22934 |
3M-011
Featured
|
3M-011 is a potent TLR7/8 agonist and cytokine inducer; stimulates type I interferon (IFN) and other cytokines such as TNF-alpha, IL-12, and IFN-gamma from rat peripheral blood mononuclear cells; induces IL-12 and COX-2 expression in mDC from HIV+ and HIV- individuals, and inhibits H3N2 influenza viral replication in the nasal cavity; potentiates NK cytotoxicity, and shows antitumor effects in scid/B6 mice and scid/NOD mice. |
|
| DC22922 |
3M-003
Featured
|
A potent TLR7/8 agonist that induces robust production of the Th1-polarizing cytokines TNF-alpha and IL-12 from neonatal antigen-presenting cells (APCs).. |
|
| DC22924 |
3M-002
Featured
|
A selective TLR8 agonist that induces activation of NF-κB at 0.4 uM. |
|
| DC23543 |
ANA975
Featured
|
ANA975 is an oral prodrug of the TLR-7 agonist Isatoribine (ANA245. |
|
| DC10276 |
C29
Featured
|
C29 is a potential TLR2 inhibitor. |
|
| DC26031 |
Gardiquimod trifluoroacetate
Featured
|
Gardiquimod trifluoroacetate is a specific TLR7 agonist which can also inhibit HIV-1 reverse transcriptase. |
|
| DC7138 |
GS-9620(Vesatolimod)
Featured
|
GS-9620 is a potent and selective orally active small molecule agonist of Toll-like receptor 7(TLR-7) in chimpanzees with chronic HBV infection. |
|
| DC8815 |
Motolimod (VTX-2337)
Featured
|
Motolimod (VTX-2337) is a novel TLR8 agonist that activates NK cells and augments ADCC. |
|
| DC10875 |
Paquinimod
Featured
|
Paquinimod is a S100A9 inhibitor, which prevents S100A9 binding to TLR-4. |
|
| DC7788 |
Resiquimod（R848）
Featured
|
Resiquimod (R-848; S28463) is a potent synthetic agonist of TLR7/TLR8 that possesses antiviral and antitumoral activities. |
|
| DC12437 |
SMU127
Featured
|
SMU127 (SMU-127, ZINC666243) is a specific TLR1-TLR2 small molecule agonist with EC50 of 0.55 uM. |
|
| DC7733 |
Tasquinimod(ABR-215050)
Featured
|
Tasquinimod is an orally active antiangiogenic agent by allosterically inhibiting HDAC4 signalling. |
|
| DC21273 |
Telratolimod
Featured
|
Telratolimod (MEDI 9197, 3M 052) is a novel, injectable, tissue-retained TLR7/8 agonist that forms a tissue depot with gradual, sustained release, allowing local TLR triggering activity without systemic cytokine release. |
|
| DC10653 |
TLR7-IN-1
Featured
|
TLR7-IN-1 is a novel TLR7 inhibitor. |
|
| DC28134 |
α-Galactosylceramide
Featured
|
α-Galactosylceramide (α-GalCer) is a synthetic glycolipid with antitumorial and immunostimulatory. α-Galactosylceramide is a very potent NKT cell agonist and binds effectively to CD1d. The complex of α-Galactosylceramide plus CD1d binds the NKT cell TCR (T cell antigen receptor). |
|
| DC28230 |
Loxoribine
Featured
|
Loxoribine (7-Allyl-8-oxoguanosine) is a guanosine analog with anti-viral and anti-tumor activities. Loxoribine is an orally bioavailable and selective Toll-like receptor (TLR) 7 agonist. |
|
| DC28351 |
1V209(TLR7 agonist T7)
Featured
|
1V209 (TLR7 agonist T7) is a Toll-like receptor 7 (TLR7) agonist and has anti-tumor effects. 1V209 can be conjugated with various polysaccharides to improve its water solubility, and enhance its efficacy, and maintain low toxicity. |
|
| DC28386 |
GSK2245035
Featured
|
GSK2245035 is a highly potent and selective intranasal Toll-Like receptor 7 (TLR7) agonist with preferential Type-1 interferon (IFN)-stimulating properties. GSK2245035 has pEC50s of 9.3 and 6.5 for IFNα and TFNα. GSK2245035 effectively suppresses allergen-induced Th2 cytokine production in human peripheral blood cell cultures. GSK2245035 is used for asthma. |
|
| DC28692 |
TLR7/8 agonist 3
Featured
|
TLR7/8 agonist 3 is a potent TLR7 and TLR8 agonist, extracted from patent US20170114137A1. |
|
| DC28932 |
Polyinosinic-polycytidylic acid sodium
Featured
|
Polyinosinic-polycytidylic acid (Poly(I:C)) sodium is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid sodium can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid sodium can directly trigger cancer cells to undergo apoptosis. |
|
| DC31025 |
TLR4-IN-C34
Featured
|
TLR4-IN-C34 is an orally active TLR4 inhibitor and reduces systemic inflammation in models of endotoxemia and necrotizing enterocolitis[1][2]. |
|
| DC31070 |
M1002
Featured
|
M1002 is a first-in-class HIF-2a agonists. |
|
| DC34454 |
Gardiquimod
Featured
|
Gardiquimod is a TLR7 agonist, inducing the activation of NF-B in HEK293 cells expressing human or mouse TLR7. |
|
| DC42507 |
CU-115
Featured
|
CU115 is a potent TLR8 antagonist (IC50=1.04 µM), and shows selective for TLR8 over TLR7 (IC50=>50 µM). CU 115 decreases TNF-α and IL-1β production activated by R-848 in THP-1 cells. |
|
| DC42749 |
AZ617
Featured
|
AZ617 is a potent TLR4 agonist. |
|
| DC44159 |
Enpatoran
Featured
|
Enpatoran (M5049) is an orally active and dual TLR7/8 inhibitor with IC50s of 11.1 nM and 24.1 nM in HEK293 cells, respectively. Enpatoran can block both innate and adaptive autoimmunity. Enpatoran is inactive against TLR3, TLR4 and TLR9. Enpatoran (M5049) can block molecule synthetic ligands and natural endogenous RNA ligands. Enpatoran (M5049) inhibits cytokine release, causing great potency in pharmacokinetic/pharmacodynamic properties. |
|
| DC45281 |
RS 09
Featured
|
RS 09 is a TLR4 agonist. RS 09 promotes NF-κB nuclear translocation and induces inflammatory cytokine secretion in RAW264.7 macrophages in vitro. RS 09 acts as an adjuvant in vivo; RS 09 enhances X-15 specific antibody serum concentrations, when administered with X-15-KLH in mice. |
|
| DC46463 |
Monophosphoryl lipid A
Featured
|
Monophosphoryl lipid A (Glucopyranosyl lipid A) is a toll-like receptor 4 agonist. Monophosphoryl lipid A is derived from the cell wall of nonpathogenic Salmonella. Monophosphoryl lipid A can be used for the research of immunization and vaccine. |
|
| DC47256 |
TJ-M2010-5
Featured
|
TJ-M2010-5 is a MyD88 inhibitor that binds to the TIR domain of MyD88 to interfere with its homodimerization, and the TLR/MyD88 signal pathway. TJ-M2010-5 can be used for the research of myocardial ischemia/reperfusion injury (MIRI). |
|
